MedTrace Logo

MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT06132256 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 145

Last updated 2026-03-27

No results posted yet for this study

Summary

The study will evaluate the efficacy and safety of axatilimab in participants with IPF.

Conditions

Interventions

DRUG

Axatilimab

Administered as intravenous (IV) infusion

OTHER

Placebo

Placebo to match axatilimab administered as IV infusion. Placebo will not contain active ingredient.

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Syndax Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-11
Primary Completion
2026-09-30
Completion
2026-11-30
FDA Drug
Yes

Countries

  • Australia
  • Belgium
  • Canada
  • Czechia
  • France
  • Germany
  • Italy
  • Poland
  • Romania
  • South Korea
  • Spain
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06132256 on ClinicalTrials.gov